Recent studies on long-acting GLP-1s in type 1 diabetes have shown promising results, including reductions in A1C levels and increased time within the target blood sugar range, without diabetic ketoacidosis or significant hypoglycemic episodes.It is well-established that elevated A1C levels can increase the risk of cardiovascular complications and kidney disease in individuals with T1D
These medications mimic a hormone your body releases after eating, which helps regulate appetite and blood sugar
Three Honest Explanations We do not yet have the randomized trial that would settle this, so Ill give you the three explanations that actually hold up, not a tidy headline
Further increases to 1.0mg, 1.7mg, and potentially 2.4mg happen at four-week intervals based on tolerance and response
But the suggestion that compounders are somehow prohibited from marketing at a certain scale raises a different question: What scale would that be
These often improve as your body gets used to the medication